Pfizer, Avant ink $440M cancer vax deal
This is a discussion on Pfizer, Avant ink $440M cancer vax deal within the Biotechnology News forum, part of the Industry News and Updates category; Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
04-17-2008, 01:04 PM
|
|||
|
|||
Pfizer, Avant ink $440M cancer vax deal
Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And Avant Read more...
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Pfizer halts Phase III cancer trial on poor results | industry_news | Biotechnology News | 0 | 04-02-2008 01:39 PM |
© 2008 DrugManagementForum™ powered by |
 |